Psyched Wellness Ltd
Recent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Psyched Wellness Ltd. is a Canada-based health supplements company focused on the production and distribution of mushroom-derived consumer packaged goods, primarily from Amanita muscaria utilizing its proprietary AME-1 water-based extract; core products include Calm (available in 30 ml and 60 ml formats as liquid extracts for stress relief, relaxation, and restful sleep), the recently launched Calmer (a higher-potency 2x version of Calm with enhanced flavor profile introduced in November 2025), and Santa (a new dietary supplement shot with initial production completed in September 2025 ahead of a soft launch and holiday season expansion). Founded in 1981 as Duncan Park Holdings Corporation and renamed Psyched Wellness Ltd. in July 2020, the company is headquartered at 36 Toronto Street, Toronto, Ontario, with registered offices at 77 King Street West, Suite 3000, and operates primarily in North America through direct-to-consumer online sales via its e-commerce platform launched in 2025, targeting the functional food and wellness sectors with products aimed at mood support and body restoration. Recent developments encompass a US$7.5 million non-brokered private placement finalized in May 2024 with Gotham Green Partners including strategic advisory partnerships, a USPTO patent application for scaled-up extraction process filed August 2025 (pending in the US and Canada), completion of genotoxicity studies and stability testing extending Calm's shelf life to 18 months announced in April 2025, a voluntary New Dietary Ingredient Notification to the FDA in July 2025 for AME-1 despite subsequent non-concurrence, board changes with a new director appointment and resignation in November 2024, and ongoing route-to-market partnership expansions for distribution.
Company News
Psyched Wellness Announces Secured Term Loan
Psyched Wellness Announces Secured Term Loan
Psyched Wellness Announces Secured Term Loan
Psyched Wellness Launches Strategic Review to Unlock Shareholder Value
Psyched Wellness Provides Corporate Update
Psyched Wellness Highlights U.S. Federal Policy Momentum Supporting Psychedelic Sector
Psyched Wellness Announces Closing of Private Placement and Shares for Debt Transaction and Resignation of a Director
Psyched Wellness Announces Private Placement for Proceeds of up to C$1,719,306.94
Psyched Wellness Sells Out of First Run of Calmer and Announces New Production Run
Psyched Wellness Launches Calmer, a 2x Version of Calm and an Enhanced Flavour Profile for Calm
Psyched Wellness Provides Comprehensive Investor Update
Psyched Wellness Provides Comprehensive Investor Update
Psyched Wellness Provides Comprehensive Investor Update
Psyched Wellness Announces Appointment of New Director and Resignation of a Director
Psyched Wellness Announces Supply Chain Disruption in the US
Psyched Wellness Adds Harmons to List of Retail Partners, Engages UNFI For Distribution, and Announces Appointment of Kyle Nazareth as Chief Financial Officer
Psyched Wellness Developing Amanita Muscaria Gummies for Sale in the USA
Psyched Wellness Announces Grant of Options
Psyched Wellness Closes Final US$2.5M Tranche of Its Non-Brokered Private Placement for a Total of US$7.5M with Gotham Green Partners and Provides Corporate Update
Psyched Wellness and Gotham Green Partners to Close Final Tranche of US$2.5M for a Total of US$7.5M Raised and Partner with Strategic Advisors to Build Consumer Packaged Goods Derived from AME-1